ACW Alzheimers pivotal trial completes last patient visit
Filed with ASX · · 3 pages · English
Summary by 6ix AI
Actinogen Medical Limited announces the completion of the final patient visit for its XanaMIA pivotal Alzheimer’s disease trial, confirming that topline results are expected in November. Dr. Dana Hilt, the Chief Medical Officer, emphasized the potential of Xanamem as a transformative treatment option for Alzheimer’s patients. The trial has now closed to participant recruitment and will report final results soon.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Actinogen Medical Limited on 6ix
Earlier from Actinogen Medical
- Notification of cessation of securities - ACW
- Application for quotation of securities - ACW
- Appendix 3Y-Dr Geoffrey Brooke
- ACW CMO international Xanamem presentation
- Response to ASX Price Query
Later from Actinogen Medical
- Options underwriting cleansing notice
- Underwriting of unlisted options completed
- Actinogen XanaMIA pivotal Alzheimer’s disease trial completes final patient visit, with topline results on track for November
- AGM date and closing date for director nominations
- Notification of buy-back - ACW
Follow Actinogen Medical into a list and get an email when it puts out news.
Follow Actinogen Medical